Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
11C-Choline PET/pathology image coregistration in primary localized prostate cancer.
Grosu AL, Weirich G, Wendl C, Prokic V, Kirste S, Geinitz H, Souvatzoglou M, Gschwend JE, Schwaiger M, Molls M, Weber WA, Treiber U, Krause BJ. Grosu AL, et al. Among authors: kirste s. Eur J Nucl Med Mol Imaging. 2014 Dec;41(12):2242-8. doi: 10.1007/s00259-014-2861-0. Epub 2014 Sep 4. Eur J Nucl Med Mol Imaging. 2014. PMID: 25186430
Clinical outcome after total neoadjuvant treatment (CAO/ARO/AIO-12) versus intensified neoadjuvant and adjuvant treatment (CAO/ARO/AIO-04) a comparison between two multicenter randomized phase II/III trials.
Diefenhardt M, Fleischmann M, Martin D, Hofheinz RD, Piso P, Germer CT, Hambsch P, Grützmann R, Kirste S, Schlenska-Lange A, Ghadimi M, Rödel C, Fokas E; German Rectal Cancer Study Group. Diefenhardt M, et al. Among authors: kirste s. Radiother Oncol. 2023 Feb;179:109455. doi: 10.1016/j.radonc.2022.109455. Epub 2022 Dec 23. Radiother Oncol. 2023. PMID: 36572280 Clinical Trial.
Adjuvant radiotherapy after salvage lymph node dissection because of nodal relapse of prostate cancer versus salvage lymph node dissection only.
Rischke HC, Schultze-Seemann W, Wieser G, Krönig M, Drendel V, Stegmaier P, Krauss T, Henne K, Volegova-Neher N, Schlager D, Kirste S, Grosu AL, Jilg CA. Rischke HC, et al. Among authors: kirste s. Strahlenther Onkol. 2015 Apr;191(4):310-20. doi: 10.1007/s00066-014-0763-5. Epub 2014 Oct 18. Strahlenther Onkol. 2015. PMID: 25326142
MRI versus ⁶⁸Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer.
Zamboglou C, Wieser G, Hennies S, Rempel I, Kirste S, Soschynski M, Rischke HC, Fechter T, Jilg CA, Langer M, Meyer PT, Bock M, Grosu AL. Zamboglou C, et al. Among authors: kirste s. Eur J Nucl Med Mol Imaging. 2016 May;43(5):889-897. doi: 10.1007/s00259-015-3257-5. Epub 2015 Nov 23. Eur J Nucl Med Mol Imaging. 2016. PMID: 26592938
Stereotactic body radiotherapy (SBRT) in recurrent or oligometastatic pancreatic cancer : A toxicity review of simultaneous integrated protection (SIP) versus conventional SBRT.
Gkika E, Adebahr S, Kirste S, Schimek-Jasch T, Wiehle R, Claus R, Wittel U, Nestle U, Baltas D, Grosu AL, Brunner TB. Gkika E, et al. Among authors: kirste s. Strahlenther Onkol. 2017 Jun;193(6):433-443. doi: 10.1007/s00066-017-1099-8. Epub 2017 Jan 30. Strahlenther Onkol. 2017. PMID: 28138949 Clinical Trial. English.
Evaluation of intensity modulated radiation therapy dose painting for localized prostate cancer using 68Ga-HBED-CC PSMA-PET/CT: A planning study based on histopathology reference.
Zamboglou C, Sachpazidis I, Koubar K, Drendel V, Wiehle R, Kirste S, Mix M, Schiller F, Mavroidis P, Meyer PT, Werner M, Grosu AL, Baltas D. Zamboglou C, et al. Among authors: kirste s. Radiother Oncol. 2017 Jun;123(3):472-477. doi: 10.1016/j.radonc.2017.04.021. Epub 2017 May 9. Radiother Oncol. 2017. PMID: 28499607
59 results